SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Robert PuckrinMarie-Philippe SaltielPauline ReynierLaurent AzoulayOriana H Y YuKristian B FilionPublished in: Acta diabetologica (2018)
SGLT-2 inhibitors are associated with an increased risk of genital tract infections. Although there is no association overall between SGLT-2 inhibitors and UTI, higher doses of dapagliflozin are associated with an increased risk.
Keyphrases